Clinical Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uzzo, R. G.
Right arrow Articles by Finke, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uzzo, R. G.
Right arrow Articles by Finke, J. H.
Clinical Cancer Research Vol. 5, 1219-1229, May 1999
© 1999 American Association for Cancer Research


Cancer Biology, Immunology, Cytokines

Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma1

Robert G. Uzzo2, Patricia Rayman, Vladimir Kolenko, Peter E. Clark, Tracy Bloom, A. Michelle Ward, Luis Molto, Charles Tannenbaum, Lydia J. Worford, Ronald Bukowski, Raymond Tubbs, Eric D. Hsi, Neil H. Bander, Andrew C. Novick and James H. Finke

Departments of Immunology [R. G. U., P. R., V. K., P. E. C., T. B., A. M. W., L. M., C. T., L. J. W., J. H. F.], Urology [R. G. U., P. E. C., A. M. W., A. C. N., J. H. F.], Clinical Pathology [R. T., E. D. H.], and Hematology-Oncology [R. B., J. H. F.], The Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, Ohio 44195, and Department of Urology, Division of Urologic Oncology, The New York Hospital-Cornell University Medical Center [N. H. B.], New York, New York 10021

Tumors may escape immune recognition and destruction through the induction of apoptosis in activated T lymphocytes. Results from several laboratories suggest that FasL (L/CD95L) expression in tumors may be responsible for this process. In this study of patients with renal cell carcinoma (RCC), we provide evidence for two mechanisms of T-cell apoptosis. One mechanism involves the induction of apoptosis via FasL expression in tumor cells. This is supported by several observations, including the fact that tumor cells in situ as well as cultured cell lines expressed FasL mRNA and protein by a variety of techniques. The FasL in RCC is functional because in coculture experiments, FasL+ tumors induced apoptosis in Fas-sensitive Jurkat T cells and in activated peripheral blood T cells but not in resting peripheral blood T cells. Most importantly, antibody to FasL partially blocked apoptosis of the activated T cells. Moreover, Fas was expressed by T cells derived from the peripheral blood (53% median) and tumor (44.3% median) of RCC patients. Finally, in situ staining for DNA breaks demonstrated apoptosis in a subset of T cells infiltrating renal tumors. These studies also identified a second mechanism of apoptosis in RCC patient peripheral T cells. Whereas these cells did not display DNA breaks when freshly isolated or after culture for 24 h in medium, peripheral blood T cells from RCC patients underwent activation-induced cell death after stimulation with either phorbol 12-myristate 13-acetate/ionomycin or anti-CD3/CD28 antibodies. Apoptosis mediated by exposure to FasL in tumor cells or through T-cell activation may contribute to the failure of RCC patients to develop an effective T-cell-mediated antitumor response.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al.
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Das, G. Sa, E. Paszkiewicz-Kozik, C. Hilston, L. Molto, P. Rayman, D. Kudo, K. Biswas, R. M. Bukowski, J. H. Finke, et al.
Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways
J. Immunol., April 1, 2008; 180(7): 4687 - 4696.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Das, G. Sa, C. Hilston, D. Kudo, P. Rayman, K. Biswas, L. Molto, R. Bukowski, B. Rini, J. H. Finke, et al.
GM1 and Tumor Necrosis Factor-{alpha}, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
Cancer Res., March 15, 2008; 68(6): 2014 - 2023.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al.
TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction
J. Immunol., May 15, 2007; 178(10): 6642 - 6652.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. E. Krambeck, H. Dong, R. H. Thompson, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, M. L. Blute, T. J. Sebo, J. C. Cheville, A. S. Parker, et al.
Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Clin. Cancer Res., March 15, 2007; 13(6): 1749 - 1756.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. H. Thompson, H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon
PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma
Clin. Cancer Res., March 15, 2007; 13(6): 1757 - 1761.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. H. Thompson, H. Dong, and E. D. Kwon
Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
Clin. Cancer Res., January 15, 2007; 13(2): 709s - 715s.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Biswas, A. Richmond, P. Rayman, S. Biswas, M. Thornton, G. Sa, T. Das, R. Zhang, A. Chahlavi, C. S. Tannenbaum, et al.
GM2 Expression in Renal Cell Carcinoma: Potential Role in Tumor-Induced T-Cell Dysfunction.
Cancer Res., July 1, 2006; 66(13): 6816 - 6825.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. H. Thompson, S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, et al.
Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up.
Cancer Res., April 1, 2006; 66(7): 3381 - 3385.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, et al.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
PNAS, December 7, 2004; 101(49): 17174 - 17179.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Donskov, H. von der Maase, N. Marcussen, S. Hamilton-Dutoit, H. H. T. Madsen, J. J. Jensen, and M. Hokland
Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No In vivo Effect of Fas Ligand Tumor Counterattack
Clin. Cancer Res., December 1, 2004; 10(23): 7911 - 7916.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. C. Flanigan
Debulking Nephrectomy in Metastatic Renal Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6335S - 6341S.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al.
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses
Clin. Cancer Res., September 15, 2004; 10(18): 6360S - 6366S.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al.
Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas
J. Immunol., March 15, 2004; 172(6): 3480 - 3490.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Molto, P. Rayman, E. Paszkiewicz-Kozik, M. Thornton, L. Reese, J. C. Thomas, T. Das, D. Kudo, R. Bukowski, J. Finke, et al.
The Bcl-2 Transgene Protects T Cells from Renal Cell Carcinoma-mediated Apoptosis
Clin. Cancer Res., September 15, 2003; 9(11): 4060 - 4068.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke
Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells
Cancer Res., April 1, 2003; 63(7): 1676 - 1683.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. E. Hutson, L. Molto, T. Mekhail, P. Elson, J. Finke, C. Tannenbaum, E. Borden, R. Dreicer, T. Olencki, and R. M. Bukowski
Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects
Clin. Cancer Res., April 1, 2003; 9(4): 1354 - 1360.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
E. C. Ibrahim, Y. Allory, F. Commo, B. Gattegno, P. Callard, and P. Paul
Altered Pattern of Major Histocompatibility Complex Expression in Renal Carcinoma: Tumor-Specific Expression of the Nonclassical Human Leukocyte Antigen-G Molecule Is Restricted to Clear Cell Carcinoma While Up-Regulation of Other Major Histocompatibility Complex Antigens Is Primarily Distributed in All Subtypes of Renal Carcinoma
Am. J. Pathol., February 1, 2003; 162(2): 501 - 508.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Saio, S. Radoja, M. Marino, and A. B. Frey
Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide
J. Immunol., November 15, 2001; 167(10): 5583 - 5593.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. C. Ibrahim, N. Guerra, M.-J. T. Lacombe, E. Angevin, S. Chouaib, E. D. Carosella, A. Caignard, and P. Paul
Tumor-specific Up-Regulation of the Nonclassical Class I HLA-G Antigen Expression in Renal Carcinoma
Cancer Res., September 1, 2001; 61(18): 6838 - 6845.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Radoja, M. Saio, and A. B. Frey
CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ
J. Immunol., May 15, 2001; 166(10): 6074 - 6083.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. R. Gastman, X.-M. Yin, D. E. Johnson, E. Wieckowski, G.-Q. Wang, S. C. Watkins, and H. Rabinowich
Tumor-induced Apoptosis of T Cells: Amplification by a Mitochondrial Cascade
Cancer Res., December 1, 2000; 60(24): 6811 - 6817.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. Austin Taylor, M. Bennett, V. Kumar, and J. D. Schatzle
Functional Defects of NK Cells Treated with Chloroquine Mimic the Lytic Defects Observed in Perforin-Deficient Mice
J. Immunol., November 1, 2000; 165(9): 5048 - 5053.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. R. Gastman, D. E. Johnson, T. L. Whiteside, and H. Rabinowich
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events
Blood, March 15, 2000; 95(6): 2015 - 2023.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. M. Bukowski, P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al.
Interferon-{{gamma}} and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma
Clin. Cancer Res., October 1, 1999; 5(10): 2780 - 2789.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.